Table 2.
The ten strongest genes with higher gene expression correlated to shorter relapse-free survival length in three colon cancer cohorts including all patients, stage II patients, and stage III and IV tumors
| Gene symbol | p value | FDR | HR | Cutoff value |
|---|---|---|---|---|
| All patients | ||||
| RBPMS | 1.1E−17 | 5.7E−16 | 2.49 | 812 |
| TIMP1 | 6.5E−17 | 3.3E−15 | 2.44 | 9,073.5 |
| COL4A2 | 4.0E−16 | 2.1E−14 | 2.35 | 4,413 |
| TAGLN | 4.4E−16 | 2.2E−14 | 2.58 | 2,601.4 |
| LOXL2 | 2.0E−15 | 6.9E−14 | 2.33 | 1,333 |
| S100A11 | 1.0E−14 | 5.1E−13 | 2.31 | 8,250.3 |
| NOTCH3 | 1.0E−14 | 5.9E−13 | 2.26 | 544 |
| FAM127A | 2.1E−14 | 1.1E−12 | 2.24 | 1,523.6 |
| LMO2 | 2.1E−13 | 7.9E−12 | 2.17 | 471 |
| SERPINE1 | 2.8E−13 | 1.8E−11 | 2.18 | 537 |
| Stage II | ||||
| CSF1R | 1.1E−06 | 1.3E−05 | 2.86 | 323.5 |
| FLNA | 1.1E−06 | 2.9E−05 | 2.88 | 764.4 |
| TPBG | 1.5E−06 | 2.6E−05 | 2.65 | 1,199.4 |
| B2M | 2.0E−06 | 1.0E−04 | 2.62 | 30,461.9 |
| LOXL2 | 2.1E−06 | 4.9E−05 | 2.63 | 1,333.0 |
| TAGLN | 4.4E−06 | 7.5E−05 | 2.75 | 2,568.7 |
| LMO2 | 7.9E−06 | 8.1E−05 | 2.48 | 403.4 |
| YWHAE | 1.1E−05 | 2.8E−04 | 2.62 | 3,600.2 |
| PLOD1 | 1.7E−05 | 1.5E−04 | 2.43 | 689.0 |
| ARRB2 | 2.4E−05 | 3.7E−04 | 2.63 | 207.3 |
| Stage III/IV | ||||
| BHLHE40 | 3.1E−08 | 6.7E−07 | 2.06 | 3,756.5 |
| COL4A2 | 2.1E−07 | 2.7E−06 | 2.02 | 4,054.0 |
| TSC22D3 | 3.7E−07 | 9.3E−06 | 1.95 | 1,522.2 |
| NPR3 | 1.9E−06 | 6.8E−05 | 1.91 | 230.8 |
| A2M | 2.6E−06 | 2.7E−05 | 1.86 | 4,767.2 |
| NR1D1 | 2.7E−06 | 3.7E−05 | 2.32 | 347.2 |
| NOTCH3 | 2.9E−06 | 1.8E−05 | 2.27 | 236.1 |
| LOXL2 | 3.7E−06 | 6.2E−05 | 1.88 | 1,166.3 |
| TAGLN | 5.7E−06 | 5.6E−05 | 2 | 2,413.7 |
| KLK6 | 6.0E−06 | 3.1E−04 | 1.85 | 203.3 |
The stage II and stage III/IV gene lists were restricted to druggable genes with at least one possible inhibitor. HR, hazard rate; FDR, false discovery rate.